Nanotechnology Now - Press Release: Abraxis Founder & Executive Chairman to Present at 7th Annual World Health Care Congress

Home > Press > Abraxis Founder & Executive Chairman to Present at 7th Annual World Health Care Congress

Abstract:
Patrick Soon-Shiong, M.D. to Deliver Keynote "Transforming Health Care Now in the Developed and Developing Worlds" with Nobel Laureate Muhammad Yunus

Abraxis Founder & Executive Chairman to Present at 7th Annual World Health Care Congress

Los Angeles, CA | Posted on April 13th, 2010

Addressing over 2,000 government and industry health care experts gathering at the 7th Annual World Health Care Congress (WHCC) on Tuesday, April 13, 2010, Patrick Soon-Shiong, M.D., founder and executive chairman of Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, will present a vision for utilizing disruptive innovation for transforming healthcare in the United States and the developing world. The conference presentations are part of the 2010 banner, "Driving Strategy in an Uncertain Era of Health Reform," being held at the Gaylord National Resort and Convention Center in Washington, D.C. In a second address, with Vicki Seyfert-Margolis, Ph.D., senior advisor, Science Innovation and Policy, at the U.S. Food and Drug Administration, Dr. Soon-Shiong will present "FDA Update on Innovation in 21st Century Product Development."

For more information go to www.worldcongress.com.

####

About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab® platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 39 countries. The company continues to expand the nab® platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.

For more information, please click here

Contacts:
Abraxis BioScience, Inc.
Investors and Media Inquiries
Maili Bergman
310-883-1300

Media Inquiries
Zeno Group
Victoria Fort
202-361-0445

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: